Sinocelltech Group (SHSE:688520) ROCE % : 20.85% (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Sinocelltech Group ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sinocelltech Group's annualized ROCE % for the quarter that ended in Sep. 2024 was 20.85%.

Sinocelltech Group ROCE % Historical Data

The historical data trend for Sinocelltech Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinocelltech Group ROCE % Chart

Sinocelltech Group Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-172.18

-75.55

-85.89

-42.09

-27.75

Sinocelltech Group Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-23.05	-81.06	53.89	33.65	20.85

Sinocelltech Group ROCE % Calculation

Sinocelltech Group's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-285.31	/	( ( (2735.876 - 1372.002)	+	(2718.536 - 2026.475) )	/ 2 )
	=	-285.31	/	( (1363.874	+	692.061)	/ 2 )
	=	-285.31	/	1027.9675
	=	-27.75 %

Sinocelltech Group's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	211.576	/	( ( (3037.661 - 2183.567)	+	(3155.544 - 1980.078) )	/ 2 )
	=	211.576	/	( ( 854.094	+	1175.466 )	/ 2 )
	=	211.576	/	1014.78
	=	20.85 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Sinocelltech Group (SHSE:688520) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sinocelltech Group ROCE % Related Terms

Thank you for viewing the detailed overview of Sinocelltech Group's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinocelltech Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinocelltech Group Ltd (SHSE:688520) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Kechuang Seventh Street, Beijing Economic and Technological Development Zone, Room 307, Building 5, Courtyard 31, Beijing, CHN, 100176

Website

http://www.sinocelltech.com

Sinocelltech Group Ltd is engaged in development and industrialization of biopharmaceutical products such as monoclonal antibodies, recombinant proteins and vaccines. The company has developed technology platforms in protein expression vectors, cell line development, serum-free medium development, stoichiometrically controlled fed-batch cell culture, process scale-up, and protein purification. Its capacities include stable CHO cell line development, cell banking and certification, serum-free and protein-free culture medium development, fed-batch cell culture process development, optimization, and process scale-up; protein purification development, and large scale production.

Executives

Xie Liang Zhi

Director

Sinocelltech Group Headlines

No Headlines